Literature DB >> 26268679

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?

Irene Virgolini1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26268679     DOI： 10.1007/s00259-015-3153-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  29 in total

1.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors:  Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

2.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Authors:  Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

3.  Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Authors:  Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

4.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

5.  Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.

Authors:  Daniel Putzer; Alexander Kroiss; Dietmar Waitz; Michael Gabriel; Tatjana Traub-Weidinger; Christian Uprimny; Elisabeth von Guggenberg; Clemens Decristoforo; Boris Warwitz; Gerlig Widmann; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-14       Impact factor: 9.236

6.  Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Authors:  Stefano Severi; Oriana Nanni; Lisa Bodei; Maddalena Sansovini; Annarita Ianniello; Stefania Nicoletti; Emanuela Scarpi; Federica Matteucci; Laura Gilardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-27       Impact factor: 9.236

7.  Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.

Authors:  E Seregni; M Maccauro; C Chiesa; L Mariani; C Pascali; V Mazzaferro; F De Braud; R Buzzoni; M Milione; A Lorenzoni; A Bogni; A Coliva; S Lo Vullo; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02       Impact factor: 9.236

8.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

9.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

Authors:  Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

10.  18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors.

Authors:  Tina Binderup; Ulrich Knigge; Annika Loft; Birgitte Federspiel; Andreas Kjaer
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531
View more
  3 in total

1.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

Review 2.  Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.

Authors:  Irene Virgolini; Michael Gabriel; Alexander Kroiss; Elisabeth von Guggenberg; Rupert Prommegger; Boris Warwitz; Bernhard Nilica; Llanos Geraldo Roig; Margarida Rodrigues; Christian Uprimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-13       Impact factor: 9.236

3.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.